The association of serum vitamin D levels with several cardiometabolic risk and aortic pulse wave velocity in elderly persons

Kutlay, Sim; Atlı, Teslime; Aydoğan, İlkay; Tutkak, Hüseyin; Nergızoğlu, Gökhan

doi:10.1016/j.eurger.2014.01.004

Cited by 3 publications

(2 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Many observational studies have reported an inverse association between low VitD levels and brachial BP in large samples from the general population [23,24,25], but also among Peruvian adolescents [26], middle-aged individuals [27], people aged >60 years and the elderly [28,29], pregnant women and women aged 20-80 years [30,31]. Similarly, the evidence from medium to large observational studies shows strong and independent inverse associations between serum VitD and cfPWV among diverse study populations [32,33,34,35,36,37,38]. Other markers of regional arterial stiffness, including increased carotid-radial pulse wave velocity and brachial-ankle pulse wave velocity, have been associated with lower VitD levels among people with type 2 diabetes mellitus (T2DM) [39,40].…”

Section: Summary Of Observational Data On the Relationship Between Sementioning

confidence: 99%

Effectiveness of Vitamin D Supplementation for Cardiovascular Health Outcomes

Veloudi

Jones

Sharman³

2016

Pulse

View full text Add to dashboard Cite

There is a plausible physiological theory, supported by many observational studies, that vitamin D supplementation should be effective for improving cardiovascular end points, such as blood pressure (BP), large artery stiffness, atherosclerosis, endothelial function and clinical events. However, results from randomised controlled trials (RCTs) have been inconsistent. In this review, we evaluated the evidence regarding the effectiveness of vitamin D supplementation for cardiovascular surrogate and hard clinical end points. RCTs were assessed in terms of sample size, duration of supplementation, baseline vitamin D level inclusion criteria (i.e., absence of vitamin D deficiency), dosage of vitamin D and population under investigation. Forty-five RCTs were identified. Eight RCTs with BP and 6 RCTs with large artery stiffness as the end points were found to comply with guidelines for the optimal design of clinical trials evaluating nutrient effects. Only 2 of the RCTs with an optimal design were effective in decreasing BP with vitamin D supplementation, although these were of moderate sample size (<150) and very short duration (8 weeks for both), whilst no RCT was effective in reducing large artery stiffness. Similar results were observed for atherosclerotic and endothelial function markers as end points. Only 1 RCT reported cardiovascular events as an end point and found neither increased nor decreased incident cardiovascular events over 7 years of follow-up. In conclusion, results from published RCTs indicate that vitamin D supplementation is ineffective in improving cardiovascular health among various patient populations, including in the presence or absence of vitamin D deficiency.

show abstract

Section: Summary Of Observational Data On the Relationship Between Sementioning

confidence: 99%

Effectiveness of Vitamin D Supplementation for Cardiovascular Health Outcomes

Veloudi

Jones

Sharman³

2016

Pulse

View full text Add to dashboard Cite

show abstract

“…Other trials have reported conflicting findings in people without diabetes [11,[30][31][32][33]. Mechanisms underlying the reduction in arterial stiffness by supplementation with both vitamin D 2 and D 3 are unestablished, but possible pathways include both direct and indirect effects on vascular cells, suppression of the renin-angiotensin-aldosterone system, effects on calcium metabolism leading to the calcification of arterial elastin and the interplay of inflammation and oxidative stress [23,31,34,35]. Our findings suggest that supplementation with either vitamin D 2 or D 3 over a 4-month period could offer a way to potentially favourably affect arterial stiffness, perhaps by inhibition of matrix metalloproteinases [36,37], and should stimulate further research to replicate these findings and to understand the mechanisms of how 25(OH)D concentrations may exert functional and structural alterations in the arterial system.…”

Section: Discussionmentioning

confidence: 99%

Effects of vitamin D₂ or D₃ supplementation on glycaemic control and cardiometabolic risk among people at risk of type 2 diabetes: results of a randomized double‐blind placebo‐controlled trial

Forouhi

Menon

Sharp

et al. 2016

Diabetes Obesity Metabolism

View full text Add to dashboard Cite

AimsTo investigate the effect of short‐term vitamin D supplementation on cardiometabolic outcomes among individuals with an elevated risk of diabetes.MethodsIn a double‐blind placebo‐controlled randomized trial, 340 adults who had an elevated risk of type 2 diabetes (non‐diabetic hyperglycaemia or positive diabetes risk score) were randomized to either placebo, 100 000 IU vitamin D2 (ergocalciferol) or 100 000 IU vitamin D3 (cholecalciferol), orally administered monthly for 4 months. The primary outcome was change in glycated haemoglobin (HbA1c) between baseline and 4 months, adjusted for baseline. Secondary outcomes included: blood pressure; lipid levels; apolipoprotein levels; C‐reactive protein levels; pulse wave velocity (PWV); anthropometric measures; and safety of the supplementation.ResultsThe mean [standard deviation (s.d.)] 25‐hydroxyvitamin D [25(OH)D]2 concentration increased from 5.2 (4.1) to 53.9 (18.5) nmol/l in the D2 group, and the mean (s.d.) 25(OH)D3 concentration increased from 45.8 (22.6) to 83.8 (22.7) nmol/l in the D3 group. There was no effect of vitamin D supplementation on HbA1c: D2 versus placebo: −0.05% [95% confidence interval (CI) −0.11, 0.02] or −0.51 mmol/mol (95% CI −1.16, 0.14; p = 0.13); D3 versus placebo: 0.02% (95% CI −0.04, 0.08) or 0.19 mmol/mol (95% CI −0.46, 0.83; p = 0.57). There were no clinically meaningful effects on secondary outcomes, except PWV [D2 versus placebo: −0.68 m/s (95% CI −1.31, −0.05); D3 versus placebo −0.73 m/s (95% CI −1.42, −0.03)]. No important safety issues were identified.ConclusionsShort‐term supplementation with vitamin D2 or D3 had no effect on HbA1c. The modest reduction in PWV with both D2 and D3 relative to placebo suggests that vitamin D supplementation has a beneficial effect on arterial stiffness.

show abstract

Overview of Nutraceuticals and Cardiometabolic Diseases following Socio-Economic Analysis

Bruno

Dovera

Ciccarone³

et al. 2022

Endocrines

View full text Add to dashboard Cite

The importance of functional food and nutraceutical products to deal with cardiometabolic diseases (CMDs) and metabolic syndrome (MetS) has gained attention in the past few years. The aim of this narrative review is to highlight the potential and effectiveness of nutraceutical in the improvement of CMDs and MetS biomarkers, alongside their burden of disease and economic health expenditure. A science database search was conducted between May and June 2021. A total of 35 studies were included in this paper. We included male and female subjects, children, and adults, in good health or with cardiovascular or metabolic disease. CMDs and MetS have gradually become worldwide health problems, becoming two of the major causes of morbidity and mortality in western countries. The results indicate a positive link between daily consumption of nutraceutical products and an improvement in cardiometabolic and anthropometric biomarkers. In this paper we included a wide range of nutraceutical products. Most of them showed promising data, indicating that nutraceuticals could provide a new therapeutic treatment to reduce prevalence and pharmaceutical expenditures attributed to CMDs and MetS. Unfortunately, there is a huge vacuum of data on nutraceutical usage, savings, and burden reduction. Therefore, further clinical and pharmaco-economic research in the field is highly required.

show abstract

The association of serum vitamin D levels with several cardiometabolic risk and aortic pulse wave velocity in elderly persons

Cited by 3 publications

References 23 publications

Effectiveness of Vitamin D Supplementation for Cardiovascular Health Outcomes

Effectiveness of Vitamin D Supplementation for Cardiovascular Health Outcomes

Effects of vitamin D₂ or D₃ supplementation on glycaemic control and cardiometabolic risk among people at risk of type 2 diabetes: results of a randomized double‐blind placebo‐controlled trial

Overview of Nutraceuticals and Cardiometabolic Diseases following Socio-Economic Analysis

Contact Info

Product

Resources

About

The association of serum vitamin D levels with several cardiometabolic risk and aortic pulse wave velocity in elderly persons

Cited by 3 publications

References 23 publications

Effectiveness of Vitamin D Supplementation for Cardiovascular Health Outcomes

Effectiveness of Vitamin D Supplementation for Cardiovascular Health Outcomes

Effects of vitamin D2 or D3 supplementation on glycaemic control and cardiometabolic risk among people at risk of type 2 diabetes: results of a randomized double‐blind placebo‐controlled trial

Overview of Nutraceuticals and Cardiometabolic Diseases following Socio-Economic Analysis

Contact Info

Product

Resources

About

Effects of vitamin D₂ or D₃ supplementation on glycaemic control and cardiometabolic risk among people at risk of type 2 diabetes: results of a randomized double‐blind placebo‐controlled trial